HIV Infections Clinical Trial
Official title:
Tuberculosis in a Multiethnic Inner City Population
To determine the incidence of tuberculosis in an inner city population, identify risk factors for TB, describe the natural history in adults and children, evaluate the effect of Mycobacterium tuberculosis (Mtb) co-infection on the progression of human immunodeficiency virus disease, and determine factors that contribute to compliance and non-compliance with prophylaxis and treatment.
BACKGROUND:
The research provided urgently needed information regarding incidence, risk factors, natural
history, molecular epidemiology, treatment, and prevention of tuberculosis in an especially
vulnerable multi-ethnic inner-city population with a high HIV seropositivity rate.
The study was part of a collaborative project on minority health, The Epidemiology, Drug
Resistance, and Therapy of Tuberculosis in a Multi-Ethnic Inner City Population with a High
HIV Seropositivity Rate. The 1993 Report of the Committee on Appropriations, House of
Representatives, encouraged the NHLBI to establish minority centers to facilitate the
diagnosis and treatment of cardiovascular diseases. The concept for the initiative was
developed by the NHLBI staff and approved by the September 1992 National Heart, Lung, and
Blood Advisory Council. The Request for Applications was released in October 1992.
DESIGN NARRATIVE:
The study was conducted prospectively and retrospectively in three groups of patients:
intravenous drug users and their sexual contacts in an already-recruited cohort; children
who received their primary care at Bellevue Hospital Medical Center; and Bellevue Hospital
Center inpatients with TB and outpatients who underwent prophylactic treatment. In addition
to environmental risk factors (e.g., hopelessness, cohabitation with tuberculosis patients
and injected drug use), host factors were investigated, including: HIV infection; immune
status among HIV- seropositive persons, as indicated by quantitative p24 antibodies; CD4,
CD8, and gammadelta T cell counts; and race, age, and nutritional status. Incidence and
risk-factors in the cohort were assessed by interview, blood draw, PPD screening, medical
record review, and anergy panel. Natural history and impact on HIV disease in adult and
pediatric populations were assessed by interviews, clinical screening and laboratory
measures. Drug sensitivity testing and RFLP typing of specimens from the two populations
were conducted, respectively, at the Bellevue Mycobacteriology Lab and the Public Health
Research Institute. Factors affecting treatment compliance were assessed by
self-administered questionnaire.
;
Observational Model: Case Control
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |